On this page

GOOD SENSE HAIR REGROWTH TREATMENT

Minoxidil · Solution

Over-the-counter ANDA Official labelling
Informational index, not medical advice. Content is reproduced from public FDA and NLM data. Always confirm against the manufacturer's current prescribing information. Report adverse events to FDA MedWatch.

Overview

Brand name
GOOD SENSE HAIR REGROWTH TREATMENT
Generic name
Minoxidil
Dosage form
Solution
Route
Topical
Marketing category
ANDA · ANDA
Labeler
L. Perrigo Company
Product type
Human Otc Drug
DEA schedule
Not scheduled
Active ingredients
2
NDC product codes
2
Packages
3
Data completeness
76% of corroborating sources present

Active ingredients

Source: NDC Directory
Active ingredients and strengths as listed in the NDC Directory.
Ingredient Strength RxCUI Monograph
Minoxidil 2 g/100mL 645146 View
Minoxidil 5 g/100mL 645146 View

Forms, strengths and routes

Source: NDC Directory
Dosage form
Solution
Route of administration
Topical
Presentations
5

Pharmacologic classes are listed in the class section below.

Pharmacologic class

Source: NDC Directory
Established pharmacologic classes (EPC), mechanisms of action (MoA), chemical structures (CS) and physiologic effects (PE).
Class Type Browse
Arteriolar Vasodilation [PE] PE All 29 members
Arteriolar Vasodilator [EPC] EPC All 29 members

Regulatory status

Source: Drugs@FDANDC Directory
Application number
075357
Application type
ANDA · Abbreviated New Drug Application
Approval date
July 30, 1999
Sponsor
L PERRIGO CO
Products on application
2
Submissions recorded
4
Products approved under application 075357.
Product Trade name Form Strength Ingredient Status TE Flags
075357-001 MINOXIDIL (FOR MEN) SOLUTION MINOXIDIL Over-the-counter —
075357-002 MINOXIDIL (FOR WOMEN) SOLUTION MINOXIDIL Over-the-counter —

Approval history

Source: Drugs@FDA
Most recent submissions on application 075357.
Type No. Action Status Date Review
Supplement 24 Labeling Approved March 30, 2016 Standard
Supplement 14 Labeling Approved October 8, 2008 —
Supplement 5 Labeling Approved July 14, 2005 —
Original application 1 Approved July 30, 1999 —

Review documents

  • 0 · Original application · July 21, 2015
  • 0 · Original application · July 30, 1999

Prescribing information

Source: openFDA Drug Labeling

Reproduced verbatim from the Structured Product Labeling submitted to the FDA (effective 20260806). This is the manufacturer's labelling text, not a summary and not advice.

HUMAN OTC DRUG · 20260806 HUMAN OTC DRUG · 20260804

Indications and Usage

openFDA Drug Labeling

Use to regrow hair on the top of the scalp (vertex only, see pictures on side of carton)

Purpose Hair regrowth treatment for men

Dosage and Administration

openFDA Drug Labeling

Directions • apply one mL with dropper 2 times a day directly onto the scalp in the hair loss area • using more or more often will not improve results • continued use is necessary to increase and keep your hair regrowth, or hair loss will begin again

Warnings For external use only. For use by men only. Flammable: Keep away from fire or flame Do not use if • you are a woman • your amount of hair loss is different than that shown on the side of this carton or your hair loss is on the front of the scalp. Minoxidil topical solution 5% is not intended for frontal baldness or receding hairline. • you have no family history of hair loss • your hair loss is sudden and/or patchy • you do not know the reason for your hair loss • you are under 18 years of age. Do not use on babies and children. • your scalp is red, inflamed, infected, irritated, or painful • you use other medicines on the scalp Ask a doctor before use if you have heart disease When using this product • do not apply on other parts of the body • avoid contact with the eyes. In case of accidental contact, rinse eyes with large amounts of cool tap water. • some people have experienced changes in hair color and/or texture • it takes time to regrow hair. Results may occur at 2 months with twice a day usage. For some men, you may need to use this product for at least 4 months before you see results. • the amount of hair regrowth is different for each person. This product will not work for all men. Stop use and ask a doctor if • chest pain, rapid heartbeat, faintness, or dizziness occurs • sudden, unexplained weight gain occurs • your hands or feet swell • scalp irritation or redness occurs • unwanted facial hair growth occurs • you do not see hair regrowth in 4 months May be harmful if used when pregnant or breast-feeding. Keep out of reach of children. If swallowed, get medical help or contact a Poison Control Center right away. (1-800-222-1222)

Do not use if • you are a woman • your amount of hair loss is different than that shown on the side of this carton or your hair loss is on the front of the scalp. Minoxidil topical solution 5% is not intended for frontal baldness or receding hairline. • you have no family history of hair loss • your hair loss is sudden and/or patchy • you do not know the reason for your hair loss • you are under 18 years of age. Do not use on babies and children. • your scalp is red, inflamed, infected, irritated, or painful • you use other medicines on the scalp

Ask a Doctor

openFDA Drug Labeling

Ask a doctor before use if you have heart disease

Stop use and ask a doctor if • chest pain, rapid heartbeat, faintness, or dizziness occurs • sudden, unexplained weight gain occurs • your hands or feet swell • scalp irritation or redness occurs • unwanted facial hair growth occurs • you do not see hair regrowth in 4 months

Active Ingredient

openFDA Drug Labeling

Active ingredient Minoxidil 2% w/v

Adverse event reports

Source: openFDA FAERS
44,695
FAERS reports mentioning this drug
as of 2026-09-25T03:42:24+00:00
A report count is not a risk measure. FAERS accepts voluntary and mandatory reports without establishing causation, and reporting is influenced by how widely a drug is used, how long it has been marketed, and media attention. FDA states that reports “do not prove that the drug caused the event”. Compare rates, not totals.

Attributed to this product's most-reported active ingredient: MINOXIDIL. Combination products with more than six active ingredients are not attributed, because a report count summed across a long ingredient list measures the list, not the medicine.

Packaging and NDCs

Source: NDC Directory
Every National Drug Code package associated with this medication. The NDC is the identifier used for dispensing, billing and pharmacovigilance in the United States.
Package NDC Product NDC Labeler Description Marketing start
0113-1032-30 0113-1032 L. Perrigo Company 3 BOTTLE, DROPPER in 1 CARTON (0113-1032-30) / 60 mL in 1 BOTTLE, DROPPER (0113-1032-16) May 25, 2021
0113-1032-40 0113-1032 L. Perrigo Company 6 BOTTLE, DROPPER in 1 CARTON (0113-1032-40) / 60 mL in 1 BOTTLE, DROPPER (0113-1032-16) July 29, 2021
0113-6500-30 0113-6500 L. Perrigo Company 3 BOTTLE in 1 CARTON (0113-6500-30) / 60 mL in 1 BOTTLE (0113-6500-00) October 24, 2025
0113-1032 0113-1032 L. Perrigo Company — May 25, 2021
0113-6500 0113-6500 L. Perrigo Company — October 24, 2025

Sources for this page

Every dataset that contributed a fact to this page.
Dataset Agency Used for
NDC Directory FDA Identity, ingredients, strengths, forms, routes, labelers, packages
Drugs@FDA FDA Application, sponsor, submissions, review documents, marketing status
Drug Labeling FDA / NLM Prescribing information reproduced above
FAERS FDA Adverse event report counts

Generated September 25, 2026 · 11 sections on this page.